A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)

ClinicalTrials.gov ID: NCT01804140

Public ClinicalTrials.gov record NCT01804140. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 30, 2026, 4:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a screening study to detect BRAF V600 mutation-positive patients for enrollment into clinical research studies of Zelboraf (vemurafenib). Tumor samples will be collected and analyzed from eligible patients with solid tumors (other than metastatic melanoma or papillary thyroid cancer) or multiple myeloma. All institutions with identified patients as defined by this screening protocol will have potential access to the separate vemurafenib protocol MO28072.

Study identification

NCT ID: NCT01804140
Recruitment status: Completed
Study type: Observational
Phase: Not listed
Lead sponsor: Genentech, Inc.; Industry
Enrollment: 662 participants

Conditions and interventions

Conditions

Multiple Myeloma, Neoplasms

Interventions

Not listed

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 2012 (Type not available)
Primary completion: Sep 2013 (Actual)
Completion: Sep 2013 (Actual)
Last update posted: Nov 2, 2016

2012 – 2013

United States locations

U.S. sites: 20
U.S. states: 10
U.S. cities: 18

Facility	City	State	ZIP	Site status
Not listed	Sedona	Arizona	86336	—
Not listed	Tucson	Arizona	85704	—
Not listed	Burbank	California	91505	—
Not listed	Rancho Cucamonga	California	91730	—
Not listed	Denver	Colorado	80218	—
Not listed	Ocala	Florida	34471	—
Not listed	Woodbury	Minnesota	55125	—
Not listed	Columbia	Missouri	65201	—
Not listed	Las Vegas	Nevada	89169	—
Not listed	Nashville	Tennessee	37232	—
Not listed	Amarillo	Texas	79106	—
Not listed	Austin	Texas	78705	—
Not listed	Dallas	Texas	75231	—
Not listed	Dallas	Texas	75237	—
Not listed	Dallas	Texas	75246	—
Not listed	Denton	Texas	76210	—
Not listed	McAllen	Texas	78503	—
Not listed	Tyler	Texas	75702	—
Not listed	Spokane	Washington	99204	—
Not listed	Yakima	Washington	98902	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01804140, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 2, 2016 · Synced Oct 30, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01804140 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →